c-Fms
CSF-1 receptor; colony stimulating factor 1 receptor; CSF-1R; CSF1R
c-FMS (CSF1R, CSF-1R) is a receptor protein-tyrosine kinase of the platelet-derived growth factor receptor (PDGFR) family. c-FMS is the cell surface receptor for IL-34 and CSF1. c-FMS has important roles in haematopoiesis, regulation of proliferation, cell survival and maturation of microglia and monocytes, as well as in controlling the overall immune response.
c-FMS is specifically expressed in osteoclasts and myelomonocytic-lineage cells, such as monocytes and macrophages, and the activation of c-FMS signaling promotes the proliferation or differentiation of these cells. It also promotes the production of inflammatory mediators, such as tumor necrosis factor-alpha (TNF-α) and interleukin 6 (IL6).
All Product Categories
-
c-Fms Related Products (147)
Related Products (147)
-
Recombinant Proteins (24)
-
Antibodies (8)
-
CSF1R-IN-12
0 ImagesCSF1R-IN-12 (compound 1) is a potent inhibitor of CSF1R. Colony stimulating factor 1 (CSF-1, also known as macrophage colony stimulating factor, M-CSF) is an important growth factor that controls bone marrow progenitor cells, monocytes, macrophages, and giants. CSF1R-IN-12 has the potential for the research of cancer diseases.
-
Plonmarlimab
0 ImagesSynonyms: TJ003234; TJM2Plonmarlimab (TJ003234) is an anti-GM-CSF monoclonal antibody. Plonmarlimab can be used for research of rheumatoid arthritis and COVID-19.
-
Anumigilimab
0 ImagesSynonyms: CSL-324
-
Namilumab
0 ImagesSynonyms: AMG-203; Anti-Human CSF2 Recombinant AntibodyNamilumab (AMG203) is a human IgG1 monoclonal antibody that binds with high affinity to the GM-CSF ligand, potently neutralizing GM-CSF. Namilumab can be used for the research of rheumatoid arthritis.
-
Adrixetinib
0 ImagesSynonyms: Q702Adrixetinib (Q702) is an orally active triple inhibitor against CSF1R, Mer, and Axl, with Kd values of 8.7 nM, 0.8 nM, and 0.3 nM, respectively. Adrixetinib acts as a potent immune modulator that remodels the tumor microenvironment. Adrixetinib increases the abundance of M1 macrophages and CD8⁺ T cells, while decreasing the levels of M2 macrophages and myeloid-derived suppressor cells (MDSCs). Adrixetinib upregulates the expression of MHC class I and E-cadherin in tumor cells. Adrixetinib shows remarkable antitumor efficacy in syngeneic mouse tumor models. Adrixetinib is suitable for the research of breast cancer, renal adenocarcinoma, colon carcinoma, and melanoma.
-
c-Fms-IN-1
0 Imagesc-Fms-IN-1 is a FMS kinase inhibitor with an IC50 of 0.0008 μM.
-
CSF1R-IN-3
0 ImagesCSF1R-IN-3 (compound 21) is a potent and orally active CSF-1R inhibitor (IC50=2.1 nM). CSF1R-IN-3 is a potent antiproliferative activity against colorectal cancer cells. CSF1R-IN-3 inhibits the progression of colorectal cancer by suppressing the migration of macrophages, reprograming M2-like macrophages to the M1 phenotype, and enhancing the antitumor immunity.
-
c-Fms-IN-10
0 Imagesc-Fms-IN-10 is the derivative of thieno [3,2-d] pyrimidine, an kinase inhibitor of FMS (Colony stimulating factor-1 receptor, CSF-1R) with IC50 of 2 nM. c-Fms-IN-10 has anti-tumor activity.
-
Gimsilumab
0 ImagesSynonyms: MORAb-022Gimsilumab (MORAb-022) is a human anti-GM-CSF monoclonal antibody. Gimsilumab has the potential for the research of COVID-19 and rheumatoid arthritis (RA).
-
cFMS Receptor Inhibitor II
0 ImagescFMS Receptor Inhibitor II is a CSF1R kinase inhibitor. CSF-1 is a cytokine.
-
CSF1R-IN-24
0 ImagesCSF1R-IN-24 (Example 134) is an orally active CSF1R inhibitor. CSF1R-IN-24 significantly inhibits the survival of human ipSC-derived microglia (hiPSC-MG).
-
BPR1R024
0 ImagesBPR1R024 is an orally active and selective colony-stimulating factor-1 receptor (CSF1R) inhibitor. BPR1R024 has potent CSF1R inhibition activity with an IC50 value of 0.53 nM. BPR1R024 can be used for the research of immuno-oncology.
-
GENZ-882706(Raceme)
0 ImagesCat. No.: HY-101526RCAS No.: 2070861-46-8Synonyms: GENZ-882706 racemateGENZ-882706(Raceme) is the racemate of GENZ-882706. GENZ-882706(Raceme) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
-
Adrixetinib TFA
0 ImagesCat. No.: HY-152830APurity: 99.26%Synonyms: Q702 TFAAdrixetinib (Q702) TFA is an orally active triple inhibitor against CSF1R, Mer, and Axl, with Kd values of 8.7 nM, 0.8 nM, and 0.3 nM, respectively. Adrixetinib TFA acts as a potent immune modulator that remodels the tumor microenvironment. Adrixetinib TFA increases the abundance of M1 macrophages and CD8⁺ T cells, while decreasing the levels of M2 macrophages and myeloid-derived suppressor cells (MDSCs). Adrixetinib TFA upregulates the expression of MHC class I and E-cadherin in tumor cells. Adrixetinib TFA shows remarkable antitumor efficacy in syngeneic mouse tumor models. Adrixetinib TFA is suitable for the research of breast cancer, renal adenocarcinoma, colon carcinoma, and melanoma.
-
Eflapegrastim
0 ImagesCat. No.: HY-P99913CAS No.: 1384099-30-2Eflapegrastim is a composite protein consisting of a genetically modified granulocyte-colony stimulating factor (GCSF) molecule linked via a chemical bond to an IgG4 Fc fragment (LAPS-carrier). Eflapegrastim targets to G-CSF receptor (c-Fms). Eflapegrastim stimulates proliferation and differentiation of neutrophil progenitor cells and maintains stable numbers of mature and functional neutrophils. Eflapegrastim also shortens the duration of neutropenia.
